2024
Brief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection
Reis K, Wolf A, Perumal R, Seepamore B, Guzman K, Ross J, Cheung Y, Amico K, Brust J, Padayatchi N, Friedland G, Naidoo K, Daftary A, Zelnick J, O'Donnell M. Brief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 96: 34-39. PMID: 38323838, PMCID: PMC11300702, DOI: 10.1097/qai.0000000000003394.Peer-Reviewed Original ResearchMultidrug-resistant tuberculosisDifferentiated service deliveryAntiretroviral therapyElectronic dose monitoring devicesAntiretroviral therapy adherenceMultidrug-resistant tuberculosis treatmentDifferentiated service delivery modelsHIV co-infectionTreatment courseCumulative adherenceTreatment challengesCo-infectionBedaquilineTreatment completionFocus groupsMedication adherenceHIVTreatmentPatterns of medication adherenceAdherenceTuberculosisSubpopulationsHIV/AIDSTreatment stageStage-specific
2022
Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS
O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, Nimmo C, Baldwin M, Boodhram R, Maharaj B, Amico KR, Naidoo K, Friedland G. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 325-332. PMID: 35195572, PMCID: PMC11077859, DOI: 10.1097/qai.0000000000002940.Peer-Reviewed Original ResearchConceptsMDR-TB treatment outcomesResistance-associated variantsTreatment outcomesAntiretroviral therapyMDR-TBART adherenceMultidrug-resistant tuberculosis treatmentHIV treatment outcomesProspective cohort studyMultidrug-resistant tuberculosisEnd of treatmentTreatment of patientsSuccessful treatment outcomeElectronic dose monitoring devicesHIV/AIDSCohort studyClinical outcomesMultivariable analysisNovel regimensMedication adherenceAdherence thresholdTuberculosis treatmentTreatment completionLow adherenceDose monitoringAdherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear association
2018
Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa
Bionghi N, Daftary A, Maharaj B, Msibi Z, Amico K, Friedland G, Orrell C, Padayatchi N, O’Donnell M. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa. BMC Infectious Diseases 2018, 18: 171. PMID: 29642874, PMCID: PMC5896111, DOI: 10.1186/s12879-018-3080-2.Peer-Reviewed Original ResearchConceptsAnti-retroviral therapySeven-day recallPill countMedication adherenceWisepill deviceTreatment regimensTB/HIV co-infected patientsHIV co-infected adultsHIV co-infected patientsDrug-resistant tuberculosis treatmentCo-infected adultsCo-infected patientsDR-TB treatmentPilot study patientsWeekly pill countsComplex treatment regimensElectronic pill boxesLevel of adherenceTB regimensAdherence supportAntiretroviral therapyHIV patientsStudy patientsMethodsEligible patientsNew antimycobacterial drugsTraining social workers to enhance patient-centered care for drug-resistant TB-HIV in South Africa
Zelnick J, Seepamore B, Daftary A, Amico K, Bhengu X, Friedland G, Padayatchi N, Naidoo K, O'Donnell M. Training social workers to enhance patient-centered care for drug-resistant TB-HIV in South Africa. Public Health Action 2018, 8: 25-27. PMID: 29581940, PMCID: PMC5858062, DOI: 10.5588/pha.17.0114.Peer-Reviewed Original ResearchDrug-resistant tuberculosisHuman immunodeficiency virusPatient-centered careHIV coinfectionSupport group facilitationTB-HIVHIV outcomesMedication adherenceImmunodeficiency virusTreatment literacyQuestionnaire scoresCareSocial workersTraining interventionBrief training interventionCoinfectionLower ratesTraining coursesPilot training courseKwaZulu-NatalUnique roleTuberculosisWorkersCourse
2016
Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV
O'Donnell MR, Daftary A, Frick M, Hirsch-Moverman Y, Amico KR, Senthilingam M, Wolf A, Metcalfe JZ, Isaakidis P, Davis JL, Zelnick JR, Brust JC, Naidu N, Garretson M, Bangsberg DR, Padayatchi N, Friedland G. Re-inventing adherence: toward a patient-centered model of care for drug-resistant tuberculosis and HIV. The International Journal Of Tuberculosis And Lung Disease 2016, 20: 430-434. PMID: 26970149, PMCID: PMC4863995, DOI: 10.5588/ijtld.15.0360.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug-resistant TBMedication adherenceNational TB Control ProgrammeDrug-resistant tuberculosisTB control programsPatient-centered modelPatient-centered careNew antimycobacterial agentsUnderstanding of adherenceHealth care systemAdherence supportTB-HIVObserved therapyImmunodeficiency virusComprehensive careTreatment outcomesTreatment supportTuberculosis diagnosticsPatientsCare systemCareAntimycobacterial agentsTreatment deliveryAdherence
2010
Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis
Friedland G. Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 55: s37-s42. PMID: 21045598, PMCID: PMC4505738, DOI: 10.1097/qai.0b013e3181f9c0b6.Peer-Reviewed Original ResearchConceptsHepatitis CDrug interactionsDrug usersDrug useActive screening programsSpecial clinical challengeIsoniazid preventive therapySubstance abusersInjection drug usePharmacodynamic drug interactionsDrug-resistant organismsTreatment of tuberculosisInfectious disease comorbiditiesHIV/AIDSPreventive therapyTreatment initiationComorbid conditionsMedication adherenceHIV pandemicScreening programClinical challengeClinician expertiseTherapeutic successClinical consequencesInfection controlAntiretroviral medication adherence and class-specific resistance in a large prospective clinical trial
Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, MacArthur RD, Chesney M, Friedland G, Mannheimer SB. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010, 24: 395-403. PMID: 20099399, PMCID: PMC2886717, DOI: 10.1097/qad.0b013e328335cd8a.Peer-Reviewed Original ResearchConceptsInitial virological failureCumulative adherenceVirological failureMedian timeNucleoside reverse transcriptase inhibitor resistanceProspective clinical trial dataInhibitor strategiesLarge prospective clinical trialsReverse transcriptase inhibitor resistanceInhibitor resistanceAntiretroviral-naive participantsProspective clinical trialsCox regression analysisTranscriptase inhibitor resistanceAntiretroviral medication adherenceProtease inhibitor resistanceClinical trial dataProtease inhibitorsMedication resistanceAntiretroviral therapyHIV RNANNRTI resistanceMedication adherenceClinical trialsGenotypic resistance
2006
HIV Medication Adherence
Friedland GH. HIV Medication Adherence. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s3-s9. PMID: 17133202, DOI: 10.1097/01.qai.0000248333.44449.ea.Peer-Reviewed Original ResearchSustained Benefit From a Long-Term Antiretroviral Adherence Intervention
Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, Schmetter B, Friedland GH. Sustained Benefit From a Long-Term Antiretroviral Adherence Intervention. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 43: s41-s47. PMID: 17091022, DOI: 10.1097/01.qai.0000245887.58886.ac.Peer-Reviewed Original ResearchConceptsAdherence supportAdherence interventionsClinical trialsMedian baseline CD4 countLong-term medication adherenceLarge randomized clinical trialsMM participantsAntiretroviral Adherence InterventionARV-naive individualsBaseline CD4 countFirst virologic failureIntervention clinical trialsRandomized clinical trialsMedication managersCD4 countVirologic failureVirologic outcomesCD4 cellsARV therapyHIV outcomesMedication adherenceMM subgroupsMM groupCluster randomizationCells/